source
- Merck reports positive mid-stage results for Hanmi-licensed MASH drugMerck announced Thursday that its dual GLP-1/glucagon agonist, which it licensed from South Korea’s Hanmi Pharmaceutical in 2020, has met its primary endpoints in a mid-stage trial for metabolic dy…
- Alethio Therapeutics raises $90 million Series A to develop antibody for essential thrombocythemiaAlethio Therapeutics, a spinout from the University of Oxford, announced a $90 million Series A financing round. The capital will fund the company’s lead program, an antibody designed to treat ess…